Hepatitis Forums

Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on March 22, 2019, 10:40:23 am

Title: Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer
Post by: Hep Editors on March 22, 2019, 10:40:23 am
Treatment with the checkpoint inhibitor Opdivo (nivolumab), with or without Yervoy (ipilimumab), before surgery for liver cancer led to complete tumor response in three of eight patients, according to interim study findings presented at the 2019 Gastrointestinal Cancers Symposium this week in San Francisco.

Over years or decades, chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes of liver injury can lead to the development of hepatocellular carcinoma (HCC), a type of primary liver cancer. HCC is often detected late and is difficult to treat. If diagnosed early, small tumors can sometimes be surgically removed (known as resection), but the recurrence rate is high.